Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

About this update from Sagimet Biosciences Inc. - Series A

[{"type":"image","alt":"Sagimet Biosciences Inc.","displaySize":"","headline":null,"caption":"Sagimet Biosciences Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/3e3b89356ea0d21f59c381949bb6af25"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AmJDa7oTdvowtNmgiL7OTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3e3b89356ea0d21f59c381949bb6af25","width":300,"height":110}},"lazy":false},{"type":"text","content":"SAN MATEO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.","length":310,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY, on February 11, 2026, with a fireside chat at 10am ET (link here).","length":132,"tagName":"p"}]},{"val":[{"type":"text","content":"Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, with a fireside chat at 9:20am ET (link here).","length":128,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":260,"olType":false},{"type":"text","content":"The Guggenheim and Oppenheimer fireside chats will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event.","length":218,"tagName":"p"},{"type":"text","content":"About Sagimet Biosciences ","length":25,"tagName":"p"},{"type":"text","content":"Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. Denifanstat, an oral, once-daily pill, met all primary endpoints in its Phase 2b FASCINATE-2 clinical trial in MASH as well as all primary and secondary endpoints in Sagimet’s license partner for China’s Phase 3 clinical trial in moderate-to-severe acne. A combination of denifanstat and resmetirom is currently being tested in a Phase 1 PK clinical trial and is planned to be developed for cirrhot...

More updates from Sagimet Biosciences Inc. - Series A